Phathom Pharmaceuticals press release (PHAT): Q3 Non-GAAP EPS of $0.04 beats by $0.01. - Revenue of $84.7M (+71.1% Y/Y) misses by $0.12M. Cash and cash equivalents totaled $184.6M at September 30, 2026. - Phathom reaffirmed FY2026 guidance for net revenue of $310Mâ$325M (c
Phathom Pharmaceuticals press release (PHAT): Q3 Non-GAAP EPS of $0.04 beats by $0.01. – Revenue of $84.7M (+71.1% Y/Y) misses by $0.12M.
Cash and cash equivalents totaled $184.6M at September 30, 2026. – Phathom reaffirmed FY2026 guidance for net revenue of $310Mâ$325M (consensus: $315.24M), gross margin
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
